MannKind | MNKD - Current Assets


MannKind reported $291.58M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Adma Biologics USD 466.51M 63.86M Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Novo Nordisk DKK 25.71B 148.69B Jun/2025
Pfizer USD 46.92B 3.22B Sep/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Xencor USD 599.82M 81.38M Dec/2025